Data released at the European Society of Medical Oncology meeting showed much progress. Here's what investors need to know.
A new breast cancer drug from Roche has shown "unprecedented" benefits in extending lives in a clinical trial.
T. Rowe expressed concern over Allergan's corporate governance amid its fight to hold off hostile acquirer Valeant.
We must break from the unwritten code of "zero accountability" on women's health, says Yetnayet Asfaw.
Get the best of CNBC in your inbox